CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced the closing of its investment in and completion of its expanded agreement with Tekmira Pharmaceuticals Corporation as a result of the achievement of Tekmira’s business combination with Protiva Biotherapeutics Inc. which occurred effective May 30, 2008. This agreement expands Alnylam’s access to key technology and intellectual property (IP) for the delivery of RNAi therapeutics with liposomal delivery technologies.
